Boston Scientific (BSX) 2025 Earnings Quality Report

Grade: C — Hypergrowth Meets Leveraged Acquisitions

Framework: Schilit *Financial Shenanigans* + Beneish M-Score + forensic accounting principles

Data: SEC EDGAR 10-K (Filed 2026-02-17, fiscal year ended December 31, 2025) + Yahoo Finance

Auditor: Ernst & Young LLP — Clean opinion (1 Critical Audit Matter)

One-line verdict: Boston Scientific is the fastest-growing large-cap medtech company. Revenue grew 19.9% to $20.07B in 2025, driven by the FARAPULSE pulsed field ablation (PFA) system for atrial fibrillation and the WATCHMAN left atrial appendage closure device — the Cardiovascular segment grew 23.2% to $13.25B, and within it Electrophysiology is now "the predominant component" of the business. Cash flow is excellent: CFFO of $4.53B grew 32% YoY to cover net income of $2.90B at 1.56x, and free cash flow of $3.40B was up 44%. But the growth came with aggressive acquisition spending — $1.59B in 2025 (Bolt Medical $782M, SoniVie $516M, plus smaller deals) after $4.64B in 2024 (Axonics, Silk Road) — and two red flags appear on the 18-check screen: cash of $1.97B covers only 17% of $11.44B in debt (C4 fail), and goodwill plus intangibles of $25.3B equal 104% of stockholders' equity (D1 fail). Serial acquirer FCF after acquisitions has been negative for 2 of 3 years (E1 watch). The Altman Z-Score of 2.82 is in the lower safe zone. Ernst & Young's Critical Audit Matter flags the valuation of acquired intangibles — the core accounting judgment in an acquisition-driven growth story.

Business: Two Segments, Cardiovascular Driving Everything

Per Item 1 of the 10-K: "Our core businesses are organized into two reportable segments: MedSurg and Cardiovascular. In the fourth quarter of 2025, an organizational change combined our legacy Cardiology and Peripheral Interventions businesses into a single Cardiovascular business."

Per the MD&A:

Urology's 23% reported growth includes meaningful contribution from the Axonics acquisition (completed November 15, 2024), which added sacral neuromodulation devices. Per the 10-K, organic Urology growth excluding Axonics was approximately 4.7%.

The Cardiovascular segment is the core story. From Item 1: "Since the launch of the FARAPULSE PFA System in 2024, we have observed rapid conversion from legacy treatment modalities to PFA. It is now the predominant component of our Electrophysiology business unit and revenue." Boston Scientific's Cardiac Rhythm Management and Electrophysiology business units, which include FARAPULSE and WATCHMAN, are the highest-growth part of a high-growth franchise.

Profitability: Scaling Beautifully

Per the consolidated statements of operations:

Gross margin of 69.0% is stable (+0.4pp). SG&A is growing slower than revenue — operating leverage is evident. R&D growing 27% is faster than revenue because BSX is reinvesting heavily in the pipeline (and expensing acquired IPR&D from Bolt and SoniVie as non-cash charges).

Net income growth of 56% in 2025 alone outpaces revenue growth of 19.9% — operating leverage plus capitalization of the earlier acquisition investments is materializing.

Cash Flow: The Scale Is Working

Per the consolidated statements of cash flows:

CFFO of $4.53B is up 32% year-over-year, comfortably outpacing revenue growth of 19.9%. The C1 check passes at 1.56x. Free cash flow of $3.40B is up 44%.

But the acquisition cash outflow is the notable number: -$1.81B (2023), -$4.64B (2024), -$1.59B (2025). Total three-year acquisition spend of $8.04B. Per the 10-K, the 2025 acquisitions were "Bolt Medical, Inc. and SoniVie Ltd. for purchase prices, net of cash acquired, of $782 million and $516 million, respectively." The 2024 deals included Axonics (urology) and Silk Road (peripheral vascular).

E1 WATCH: FCF after acquisitions has been negative in 2 of the past 3 years — BSX free cash flow of $3.40B was less than acquisition spending of $4.64B in 2024 and was close to offset in 2023.

Balance Sheet: Goodwill Rising, Cash Tight

Per the balance sheet:

C4 FAIL: Cash of $1.97B covers 17% of debt of $11.44B. Cash has improved from $414M a year ago but remains below 20% of debt.

D1 FAIL: Goodwill + intangibles of $25.3B equal 104% of stockholders' equity of $24.2B. Acquisitions have added $5.3B of goodwill over three years (2022: $12.9B; 2025: $18.3B).

D2 PASS: Debt/EBITDA of 2.2x is comfortable. This is the critical leverage metric, and BSX's EBITDA growth has kept pace with debt growth.

E2 PASS: Goodwill + intangibles grew 6% YoY — a relatively modest annual increase given the acquisition activity, because some earlier acquired IPR&D has been expensed or reclassified.

The 18-Point Screening

Beneish M-Score components: DSRI 0.954 (below 1.0 — receivables actually declined relative to sales, a good sign), GMI 0.994, AQI 0.953, SGI 1.199 (sales growth index reflecting 19.9% revenue growth), DEPI 1.098, SGAI 0.960 (SG&A per sales declining), TATA -0.0375, LVGI 0.974.

The SGI of 1.199 is high but mechanically driven by real revenue growth. The other components are all in the normal range. BSX's M-Score of -2.52 sits comfortably below the -2.22 threshold.

Altman Z-Score 2.82: safe zone (barely). Components: X1 working capital/assets 0.05, X2 retained earnings/assets 0.21, X3 EBIT/assets 0.09, X4 equity/liabilities 1.24. The low X1 and X2 reflect the large intangible balance and cumulative acquisition losses that haven't yet fully flowed through retained earnings.

Key Risks from the 10-K (Item 1A)

1. FARAPULSE Competitive Response

BSX's Electrophysiology leadership depends on FARAPULSE's first-mover advantage in pulsed field ablation. Medtronic has launched Affera (Spheras/Affera) and Johnson & Johnson's Varipulse is launching. Abbott's Volt PFA is in clinical trials. Any share loss to competitors would directly impact the Cardiovascular segment's growth trajectory.

2. EU MDR Implementation Costs

Per the MD&A: "We began our EU MDR implementation efforts in late 2019 and have incurred cumulative expenses of $464 million through December 31, 2025." European medical device regulation has been a significant and ongoing cost. The 10-K warns these costs will continue.

3. Integration of Multiple Acquisitions

BSX completed major acquisitions of Axonics, Silk Road Medical, Bolt Medical, and SoniVie within a 15-month window. Integration risk, cultural disruption, and the Beijing-based SoniVie's regulatory timeline to U.S. approval are all material. Ernst & Young's CAM directly addresses the acquired-intangibles valuation for these deals.

4. Operating Leverage Versus Leverage

Debt/EBITDA of 2.2x is healthy at current EBITDA levels. If growth decelerated and EBITDA fell back toward $4B, the ratio would rise toward 3x. Interest expense of $349M has grown 32% over two years.

5. Capital Spending for Manufacturing

Per the 10-K, BSX continues to invest in U.S. manufacturing ($1,919M in U.S. long-lived assets, up from $1,461M), Ireland ($750M), and Costa Rica ($637M). CapEx of $1.13B is well above the historical $800M run-rate. Growth-driven capex is positive, but cash deployment competes with acquisitions.

Auditor's Critical Audit Matter: Acquired Intangibles Valuation

Ernst & Young has audited Boston Scientific since 1992 — 33 years. The 2025 audit identified one Critical Audit Matter: Valuation of intangible assets acquired in business combinations.

Per the audit report: "As disclosed in Note B to the consolidated financial statements, during 2025, the Company completed the acquisitions of Bolt Medical, Inc. and SoniVie Ltd. for purchase prices, net of cash acquired, of $782 million and $516 million, respectively. Auditing the Company's accounting for its business combinations was complex due to the significant estimation required by management to determine the fair value of identified intangible assets, which consisted of $720 million of in-process research and development ('IPR&D') and $142 million of developed technology."

EY explains the judgment: "The significant assumptions used to estimate the fair value of the intangible assets included certain assumptions that form the basis of the forecasted results, including revenue growth rates and probability of regulatory success. These significant assumptions are forward-looking and could be affected by future economic and market conditions."

This is the right CAM for a serial acquirer. Of the $1.3B purchase price for Bolt and SoniVie, $720M was allocated to IPR&D — meaning the majority of the purchase price is forward-looking value tied to FDA approval and commercial adoption probabilities. A change in the probability of regulatory success or projected peak revenue would trigger impairment.

Key Financial Trends (4-Year)

Summary

Grade: C. Two balance-sheet red flags and one acquisition-related watch, on a company growing 20% organically with strong cash conversion.

Boston Scientific is a genuinely exceptional operating business. Revenue grew 19.9% in 2025 with Cardiovascular (FARAPULSE, WATCHMAN) expanding 23.2%. Gross margin of 69.0% is stable. CFFO of $4.53B grew 32%. Free cash flow of $3.40B grew 44%. Net income of $2.9B is up 82% from 2023. There is no accounting concern in these numbers — the M-Score of -2.52 passes the manipulation threshold, the Beneish components are all in normal range, and EY's clean opinion with 33 years of audit tenure supports the disclosed financials.

The two failures and one watch are all acquisition-related:

Ernst & Young's Critical Audit Matter directly addresses this: the valuation of acquired intangibles depends on "revenue growth rates and probability of regulatory success" assumptions that are "forward-looking and could be affected by future economic and market conditions." If FARAPULSE market share peaks, or if Medtronic Affera and J&J Varipulse capture meaningful share, several of these acquired-intangible valuations would need to be revisited.

The earnings quality question is not about the reported numbers — it is about whether the growth rates that justified the acquisition purchase prices will be sustained. Read the 10-K. Read Note B on business combinations. Read the PFA competitive discussion. Then decide whether 20% growth with 2.2x Debt/EBITDA is the beginning of a multi-year expansion or the peak of a cycle.

**Disclaimer**: This report is based on Boston Scientific's fiscal year 2025 10-K filed with the SEC on February 17, 2026. This is NOT investment advice.

**About EarningsGrade**: We screen earnings reports for financial red flags using an 18-point forensic framework. Grade C means a limited number of specific items warrant investigation.